Shots: The approval is based on P-III IMpower130 study assessing Tecentriq + CT vs CT as monothx. in 681 chemotherapy-naïve patients with stage IV metastatic non-sq NSCLC with no EGFR […]readmore
Tags : Abraxane
Shots: The approval is based on P-III IMpassion130 study assessing Tecentriq + nab-paclitaxel vs PBO + nab-paclitaxel in 902 patients in ratio (1:1) with unresectable locally advanced or metastatic TNBC […]readmore
Biotech
Regulatory
Roche’s Tecentriq (atezolizumab) + Abraxane Receives CHMP’s Recommendation for its
Shots: The CHMP recommendation is based on P-III IMpassion130 study results assessing Tecentriq + Abraxane vs PBO + Abraxane in patients with 902 patients in ratio (1:1) with unresectable LA […]readmore
Shots: The accelerated approval is based on P-III IMpassion130 study assessing Tecentriq + Abraxane vs PBO + Abraxane in 902 patients with PD-L1+ advanced or mTNBC with no prior therapy […]readmore